Stevanato Group S.p.A. (NYSE: STVN)

Stevanato Group S.p. A. is a leading global provider of drug containment, drug delivery, and diagnostic solutions, together with engineering solutions, for the pharmaceutical, biotechnology, and life sciences industries. The company offers an integrated, end to end portfolio that supports customers across the entire drug product life cycle, from research and development through commercialization.

Revenue is generated primarily through the sale of drug containment products such as prefillable syringes, vials, cartridges and ampoules; drug delivery systems including autoinjectors, pen injectors and onbody delivery systems; diagnostic consumables and equipment; and engineering machinery for assembly, packaging, visual inspection and glass converting. In 2025, approximately 88 % of total revenue came from the Biopharmaceutical and Diagnostic Solutions segment and the remaining 12 % from the Engineering segment. Customers are mainly pharmaceutical and biotechnology companies, as well as contract manufacturers and other life science firms.

The company operates through the following segments: Biopharmaceutical and Diagnostic Solutions and Engineering.

• Biopharmaceutical and Diagnostic Solutions: This segment provides drug containment solutions such as prefillable syringes, vials, cartridges and ampoules; drug delivery systems including autoinjectors, pen injectors and onbody delivery systems; diagnostic consumables and equipment; and related services such as analytical and regulatory support.

• Engineering: This segment designs, manufactures and sells machinery for assembly, packaging, visual inspection and glass converting, used in pharmaceutical, biotechnology and life sciences production processes.

Stevanato Group S.p. A. holds a leading position in the drug containment, delivery and diagnostic markets, ranking among the top three providers globally in several product lines such as prefillable syringes and ready to use vials. The company competes with firms such as Schott, Becton Dickinson, Gerresheimer, Nipro, West Pharmaceutical, SHL, Ypsomed and Syntegon. Its competitive advantages stem from an integrated end to end offering, a reputation for high quality and reliability, extensive research and development capabilities, and a global manufacturing footprint spanning approximately 65 countries.

Stevanato Group S.p. A. serves a diversified customer base of more than 700 companies worldwide, including 23 of the top 25 pharmaceutical corporations, six of the top ten in vitro diagnostic firms and seven of the top ten biotechnology businesses by market capitalization, as well as over 100 additional biotechnology customers and numerous contract manufacturers.